368 related articles for article (PubMed ID: 31514971)
1. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
[TBL] [Abstract][Full Text] [Related]
2. Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.
Yu M; Mody R; Landó LF; Shui A; Kallenbach L; Slipski L; de Oliveira CP
Clin Ther; 2017 Dec; 39(12):2399-2408. PubMed ID: 29196084
[TBL] [Abstract][Full Text] [Related]
3. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain.
Conget I; Mauricio D; Ortega R; Detournay B;
BMJ Open; 2016 Jul; 6(7):e010197. PubMed ID: 27466235
[TBL] [Abstract][Full Text] [Related]
5. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
[TBL] [Abstract][Full Text] [Related]
6. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
[TBL] [Abstract][Full Text] [Related]
9. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
[TBL] [Abstract][Full Text] [Related]
10. Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.
Boye KS; Stein D; Matza LS; Jordan J; Yu R; Norrbacka K; Hassan SW; García-Pérez LE
Drugs R D; 2019 Jun; 19(2):213-225. PubMed ID: 31115873
[TBL] [Abstract][Full Text] [Related]
11. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
12. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
13. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
Goldenberg RM; Berard L
Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
[TBL] [Abstract][Full Text] [Related]
14. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
[TBL] [Abstract][Full Text] [Related]
15. The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes.
Boye KS; Mody R; Lage MJ; Malik RE
Clin Ther; 2020 Sep; 42(9):1812-1817.e2. PubMed ID: 32741645
[TBL] [Abstract][Full Text] [Related]
16. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
[TBL] [Abstract][Full Text] [Related]
18. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
[TBL] [Abstract][Full Text] [Related]
19. Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink.
Jameson K; D'Oca K; Leigh P; Murray-Thomas T
Curr Med Res Opin; 2016; 32(1):49-60. PubMed ID: 26428701
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
